Evidence map›Paper›PMID 40696259›Full record

ReviewJournal of neuro-oncology2025

Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.

Matthew Abikenari, Justin Liu, Joseph H Ha, Shreyas Annagiri, Vratko Himic, Ravi Medikonda, Lily Kim, John Choi, Michael Lim

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew AbikenariDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Justin Liu *Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Joseph H Ha *Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Shreyas AnnagiriDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Vratko HimicDepartment of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Ravi MedikondaDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Lily KimDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
John ChoiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Michael LimDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. mklim@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging cell-based therapies represent a promising advancement in neurosurgical oncology, offering novel therapeutic possibilities for challenging diagnoses such as high-grade gliomas. Traditional treatment modalities, including surgical resection, chemotherapy, and radiotherapy, offer limited efficacy due to the highly infiltrative nature and genomic heterogeneity of malignant brain tumors. The recent integration of molecular profiling and genotypic characterization into diagnostic and therapeutic frameworks underscores a significant evolution toward personalized medicine. Stem-cell-based approaches, notably neural and mesenchymal stem cells, demonstrate remarkable tropism for pathological tissues, providing innovative strategies for targeted therapeutic delivery and intrinsic anti-tumoral effects. Concurrently, immunotherapeutic advancements, particularly immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR T-cell) therapies, and tumor vaccination techniques, have significantly altered therapeutic paradigms by leveraging patient-specific immune responses with minimal systemic toxicity. To contextualize such therapeutic innovations, we systematically reviewed and analyzed 28 ongoing glioblastoma clinical trials initiated since 2022 investigating cell-based strategies. This dataset elucidates key patterns in trial design, cellular targets, and combinatorial immunotherapeutic regimens. Despite the immense clinical promise, integrating cell-based and immunological therapeutics necessitates careful ethical deliberation and complex clinical management strategies, particularly when combined with conventional therapies. This review critically evaluates contemporary advancements, highlights emerging clinical trial outcomes, explores the ethical dimensions of novel therapeutics, and underscores the imperative for continued translational research to refine patient-specific therapeutic paradigms in neurosurgical oncology.

Indexed as

Brain NeoplasmsCell- and Tissue-Based TherapyNeurosurgeryNeurosurgical ProceduresTranslational Research, BiomedicalHumansImmunotherapyCAR T-cellCell-based therapyCheckpoint inhibitorsEthical considerationsGlioblastomaImmunotherapyNeurosurgical oncologyPatient-stratified treatmentStem cellsTranslational neurosurgery

Identifiers

PMID40696259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.